Shockwave Medical, Inc. Completes Acquisition of Neovasc
Shockwave Medical Completes Acquisition of Neovasc
Neovasc Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Corporate Update
Neovasc Shareholders Approve Acquisition by Shockwave Medical
A Bull Market Is Coming: 1 Outstanding Growth Stock Down 36% to Buy and Hold
Neovasc Announces German Reimbursement Renewal
Mergers and Acquisitions in 2023 Off To A Strong Start
Shockwave Medical To Buy Neovasc: Details (NVCN)
Shockwave Medical to Acquire Neovasc
Neovasc (NVCN) is on the Move, Here's Why the Trend Could be Sustainable
Recent Price Trend in Neovasc (NVCN) is Your Friend, Here's Why
Neovasc Announces Progress on COSIRA-II Clinical Trial
Neovasc Comments on European Heart Journal Publication
Neovasc (NVCN) Reports Q3 Loss, Misses Revenue Estimates
Neovasc Inc. (NVCN) Q3 2022 Earnings Call Transcript
Neovasc Announces Third Quarter Financial Results and Provides Corporate Update
Neovasc Reducer Obtains U.S. Outpatient Reimbursement
Neovasc Provides Corporate Update Following Clinical Data Release
Neovasc to Participate in LSI Europe 2022 Emerging MedTech Summit
Neovasc Comments on New ICD-10-CM Diagnosis Codes for Refractory Angina
Neovasc Announces Key Events at TCT 2022
Neovasc to Participate in H.C. Wainwright 24th Annual Global Investment Conference
Neovasc Inc. (NVCN) CEO Fred Colen on Q2 2022 Results - Earnings Call Transcript
Neovasc Announces Second Quarter Financial Results and Provides Corporate Update
Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations
Neovasc Announces Direct Sales Operations in United Kingdom
Neovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference
Neovasc to Participate in H.C. Wainwright Global Investment Conference
Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule
Neovasc Inc. (NVCN) CEO Fred Colen on Q1 2022 Results - Earnings Call Transcript
Neovasc (NVCN) Reports Q1 Loss, Misses Revenue Estimates
Neovasc Announces First Quarter Financial Results and Provides Corporate Update
Neovasc to Report First Quarter Financial Results on May 12, 2022
Neovasc Announces Effective Date of Share Consolidation
Neovasc to Participate in Bloom Burton & Co. Healthcare Investment Conference
Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders
Neovasc Announces Consolidation and Extension of Convertible Debt
Neovasc Inc.'s (NVCN) CEO Fred Colen on Q4 2021 Results - Earnings Call Transcript
Neovasc Announces Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Corporate Update
Neovasc to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
Neovasc Announces German Reimbursement Renewal and Commercial Progress
Independent Publication Reports Neovasc Reducer™ Demonstrates Cost Savings
Independent Publication Reports Neovasc Reducer(TM) Demonstrates Cost Savings
Neovasc Announces Complete Dismissal of Securities Class Action Complaint with Prejudice
Neovasc Announces Publication Supporting the Neovasc Reducer™ Device
Neovasc Announces Publication Supporting the Neovasc Reducer(TM) Device
Neovasc Announces Case Series of First U.S. Reducer Implants Published In Peer-Reviewed Journal
Neovasc to Participate in H.C. Wainwright BIOCONNECT Virtual Conference
Neovasc Announces First Patient Enrollment in COSIRA-II Trial
Neovasc to Participate in Sidoti December Virtual Microcap Conference